BIOCRYST PHARMACEUTICALS INC BCRX Income Statement

Biocryst pharmaceuticals inc (BCRX)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenues:
Revenues
47,771	48,835	11,839	11,518	22,564	20,653	21,814	29,120	19,725	25,186	30,279	29,282	30,970	26,353	21,972	25,196	46,251	48,257	49,101	41,352	16,976	13,608	18,729	17,880	17,235	17,331	10,865	14,237	17,626	26,293	27,416	26,904	26,429	19,643	26,419	28,786	0	0	0
Expenses
Cost of product sales
-	3,726	0	0	0	-	-	-	-	-	0	-	-	-	0	-	-	1,368	1,361	15	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
109,442	107,068	103,725	100,611	93,940	84,888	78,381	73,884	68,633	66,962	62,196	58,792	57,199	61,008	67,897	73,859	76,217	72,758	72,221	65,190	59,733	51,796	48,510	43,451	43,911	41,943	35,505	39,600	40,850	49,160	54,677	57,706	59,371	57,249	62,143	61,779	0	0	0
Selling, general and administrative
46,748	37,121	31,122	27,310	28,143	29,514	29,722	25,142	18,484	13,933	11,796	11,209	11,099	11,253	11,413	11,388	12,198	13,047	12,374	11,455	9,934	7,461	7,073	6,598	6,017	6,007	8,580	8,834	9,011	9,130	6,858	8,220	10,147	11,981	13,813	14,069	0	0	0
Royalty
357	375	201	201	418	471	530	627	406	560	586	614	619	402	268	130	545	528	550	545	108	121	95	95	94	98	195	0	0	-	0	-	-	-	-	-	-	-	-
Total operating expenses
158,874	148,290	136,447	129,521	123,900	114,873	108,633	100,795	88,665	82,597	78,017	72,912	71,214	74,960	79,585	86,730	90,313	87,701	86,507	77,206	69,791	59,379	55,678	50,144	50,022	48,048	45,943	50,406	51,829	60,181	61,649	65,926	69,518	69,230	75,956	75,848	0	0	0
Loss from operations
-111,103	-99,455	-124,608	-118,003	-101,336	-94,220	-86,819	-71,675	-68,940	-57,411	-47,738	-43,630	-40,244	-48,607	-57,613	-61,534	-44,062	-39,444	-37,406	-35,854	-52,815	-45,771	-36,949	-32,264	-32,787	-30,717	-35,078	-36,169	-34,203	-33,888	-34,233	-39,022	-43,089	-49,587	-49,537	-47,062	0	0	0
Interest and other income
7,783	1,933	2,231	2,440	2,386	2,252	2,044	1,658	1,368	1,015	635	519	463	793	863	888	857	535	410	290	193	93	71	75	77	93	112	148	184	222	265	303	382	413	456	501	0	0	0
Interest expense
12,213	11,892	11,219	10,521	9,681	9,176	8,993	8,787	8,686	8,565	8,465	7,790	7,117	6,487	5,694	5,470	5,355	5,200	5,176	5,152	5,071	4,998	4,926	4,900	4,840	4,778	4,716	4,691	4,686	4,666	4,646	4,640	4,646	3,774	0	0	0	-	-
(Loss) gain on foreign currency derivative
91	517	-111	372	2,102	-108	405	-96	-1,082	-821	4,826	3,765	367	-843	-6,332	-5,753	-2,127	1,090	5,616	10,050	7,477	5,487	2,858	-1,127	1,811	5,294	3,950	3,281	1,170	-749	-2,605	-2,619	-2,620	-4,000	0	0	0	-	-
Net loss
-115,442	-108,897	-133,707	-125,712	-106,529	-101,252	-93,363	-78,900	-77,340	-65,782	-50,742	-47,136	-46,531	-55,144	-68,776	-71,869	-50,687	-43,019	-36,556	-30,666	-50,216	-45,189	-38,946	-38,216	-35,739	-30,108	-35,732	-37,431	-37,535	-39,081	-41,219	-45,978	-49,973	-56,948	-54,621	-50,355	0	0	0
Weighted average shares outstanding (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59,589	-	57,124	53,468	51,073	50,912	50,661	49,218	47,105	-	45,178	45,111	-	44,884	44,517
Unrealized (loss) gain on available for sale investments
103	336	470	493	387	-54	-393	-437	-473	-231	-39	-61	-51	194	23	138	38	-76	-3	-95	8	-134	0	-3	-13	-23	-38	-34	-34	-13	-8	-50	-32	-65	0	0	0	-	-
Net comprehensive loss
-115,339	-108,561	-133,237	-125,219	-106,142	-101,306	-93,756	-79,337	-77,813	-66,013	-50,781	-47,197	-46,582	-54,950	-68,753	-71,731	-50,649	-43,095	-36,559	-30,761	-50,208	-45,323	-38,946	-38,219	-35,752	-30,131	-35,770	-37,465	-37,569	-39,094	-41,227	-46,028	-50,005	-57,013	0	0	0	-	-
Basic and diluted net loss per common share (in dollars per share)
-0.24	0.02	-0.34	-0.34	-0.28	-0.25	-0.28	-0.19	-0.26	-0.20	-0.18	-0.21	-0.19	-0.06	-0.16	-0.22	-0.31	-	-0.20	-	-0.21	-	-0.12	-	-0.17	-0.09	-0.14	-0.23	-0.09	-0.22	-0.19	-0.25	-0.13	-0.29	-0.32	-0.36	-0.29	-0.24	-0.23
Basic net (loss) income per common share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.07	-	-	-	-0.23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted net (loss) income per common share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.06	-	-	-	-0.23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares outstanding, basic (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72,642	-	-	-	63,647	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares outstanding (in shares)
154,156	131,479	110,416	110,338	110,167	109,951	105,410	98,787	98,592	98,649	83,570	80,418	75,167	73,766	73,734	73,695	73,601	69,241	73,262	76,760	72,341	-	71,801	63,647	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product [Member]
Revenues
16,072	17,533	0	0	0	-	-	-	-	-	0	-	-	-	0	-	-	6,291	6,236	537	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty [Member]
Revenues
5,926	6,303	5,301	5,316	4,762	6,101	7,617	7,536	7,883	10,543	10,914	13,973	14,113	9,682	6,630	3,255	2,758	2,386	2,850	2,729	2,722	3,025	2,471	2,474	2,459	2,562	2,511	5,351	5,241	3,317	0	0	0	-	-	-	-	-	-
Collaborative and Other Research and Development [Member]
Revenues
25,773	24,999	4,524	4,523	16,123	14,552	14,197	20,083	10,341	13,142	15,595	13,040	14,588	14,402	15,287	16,187	37,739	39,580	39,982	38,053	13,684	10,550	16,258	15,406	14,776	14,769	8,354	8,886	12,385	22,976	24,568	26,904	26,429	19,643	26,419	28,786	0	0	0